Jordyn Sava is an assistant editor for Targeted Oncology.
Immune Checkpoint Inhibitors Demonstrate Safety in Genitourinary Cancers
In an interview with Targeted Oncology, Brian Ramnaraign, MD, further discussed the safety of immune checkpoint inhibitors in patients with genitourinary cancers.
FDA Grants Permission to Proceed Studies of Roginolisib Across Cancer Types
Roginolisib, a first-in-class small molecule allosteric modulator of PI3Kδ, has been given the green light by the FDA to continue studies for patients with solid and hematologic malignancies.
Vimseltinib Shows Statistically Significant Improvement in 25-Week ORR in TGCT
The phase 3 MOTION study met its primary end point of objective response rate at week 25, as well as key secondary end points, when patients with tenosynovial giant cell tumor were given vimseltinib.
Bridging Science and Compassion in Cancer Care
In the second episode of Emerging Experts, Hemali Batra-Sharma, MD, discusses her passion for oncology and some of the experiences that have helped to shape her career.
Noncovalent BTK Inhibitors May Fill Unmet Medical Need in CLL
In an interview with Targeted Oncology, Skye Montoya discussed noncovalent Bruton's tyrosine kinase inhibitors and mechanisms of resistance in chronic lymphocytic leukemia.
Phase 2 of TACTIC-2 Begins Dosing TAC01-HER2 in HER2+ Gastric/GEJ Cancer
TAC01-HER2, an autologous TAC-T cell lead asset made to target HER2 in relapsed or refractory gastric and gastroesophageal junction tumors, is being further evaluated in phase 2 of the TACTIC-2 study.
Phase 2 GUIDANCE Trial of R-CHOP-X Meets Primary End Point in DLBCL
In the phase 2 GUIDANCE-01 trial, R-CHOP combined with targeted agents led to a higher response rate vs R-CHOP alone in patients with high-risk diffuse large B-cell lymphoma.
FDA Greenlights Toripalimab in Advanced Nasopharyngeal Carcinoma
Toripalimab in combination with gemcitabine and cisplatin, as well as toripalimab monotherapy, has been granted approval by the FDA for patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma.
Worden Reviews Positive Data of Cabozantinib in RAI-Refractory DTC
In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.
Liver Cancer Awareness Month: Understanding and Treating HCC
October is Liver Cancer Awareness Month, and strides continue to be made in the realm of liver cancer diagnosis and treatment. Two experts, Joan Culpepper-Morgan, MD, and Susanne G. Warner, MD, shed light on some of the treatment options available in the space.
Gemcitabine/Cisplatin/Nivolumab as Bladder Sparing Therapy in MIBC
A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with muscle-invasive bladder cancer.
FDA Accepts IND Application of MB-109 for GBM and High-Grade Astrocytoma
Preclinical data of MB-109 from the American Association for Cancer Research Annual Meeting in 2022 support MB-109 as a potential treatment for patients with recurrent glioblastoma.
FDA Grants Orphan Drug Designation to TTX101 in Malignant Gliomas
TTX101 will be studied in a phase 1/2a clinical trial for patients with recurrent glioblastoma.
Navigating Complexities and Options in the SCLC Treatment Landscape
In an interview with Targeted Oncology, Federico Albrecht, MD, discussed advances to treatments for patients with small cell lung cancer and considerations when treating difficult cases.
Dato-Dxd Significantly Improves PFS in HR+/HER2-Low or HER2– Breast Cancer
The primary end point of progression-free survival was met in TROPION-Breast01, a phase 3 study of datopotamab deruxtecan for patients with hormone receptor-positive/HER2-negative breast cancer.
FDA Approves Ivosidenib for IDH1-Mutated MDS
Ivosidenib tablets have received FDA approval for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation.
Cilta-Cel Continues to Elicit Positive Responses in R/R Multiple Myeloma
In an interview with Targeted Oncology, Yi Lin, MD, PhD, discussed the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Enzalutamide/Leuprolide Superior to Leuprolide for MFS in nmCSPC
The combination of enzalutamide and leuprolide improved metastasis-free survival and preserved quality-of-life for patients with prostate cancer with high-risk biochemical recurrence.
Tepotinib Continues to Show Positive Outcomes in METex14-Skipping NSCLC
In the VISION trial, tepotinib led to clinically meaningful results in treatment-naïve and pretreated patients with METex14-skipping non–small cell lung cancer, supporting the use of MET inhibitors for this patient population.
Lenvatinib Plus Pembrolizumab Shows Clinically Relevant Efficacy in ccRCC
In the phase 3 CLEAR study, lenvatinib combined with pembrolizumab continued to elicit deep and durable tumor response among patients with advanced clear cell renal cell carcinoma.
Screening and Vaccination are Key to Prevent Cervical Cancer
In an interview, John Diaz, MD, discusses updates to the cervical cancer treatment landscape and where the field is moving to potentially eradicate this disease in the United States.
Part B of VISTA-101 Doses KVA12123 in First Patient With a Solid Tumor
The safety, tolerability, pharmacokinetics, immunogenicity, and tumor response of KVA12123 alone and with pembrolizumab are being evaluated in a phase 1/2 study for patients with advanced solid tumors.
Modakafusp Alfa Shows Early Promise in RRMM
In an interview with Targeted Oncology, Dan T. Vogl, MD, MSCE, discussed a phase 1 study which evaluated modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.
Dosing Begins in Phase 1a/1b Study of IMGS in R/R Solid Tumors
A phase 1a/1b trial of IMGS-001 in patients with locally advanced or metastatic solid tumors is ongoing at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Survival Data Supports Use of Avelumab in Advanced Urothelial Carcinoma
A post hoc analysis of overall survival and progression-free survival support the use of avelumab with best supportive care as a standard of care for patients with urothelial carcinoma.
Phase 3 ALINA Study of Alectinib Shows DFS Benefit in ALK+ NSCLC
The phase 3 ALINA study of alectinib is the first to show an improvement in its primary end point of disease-free survival among patients with early-stage resected ALK-positive non–small cell lung cancer.
Study of Tislelizumab/Chemo Meets Primary End Points in Resectable NSCLC
Major pathological response and pathological complete response data from the phase 3 RATIONALE 315 study in NSCLC will be presented at the European Society for Medical Oncology Congress 2023.
Utilization of PARP Inhibitors in Prostate Cancer
In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.
Tislelizumab With Chemotherapy Improves OS in Advanced Gastric/GEJ Cancer
New data from the phase 3 RATIONALE 305 trial of tislelizumab with chemotherapy show potential of the combination for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.
DOC1021 Gains FDA Fast Track Designation in Glioblastoma Multiforme
A fast track designation has been granted to DOC1021 by the FDA for the treatment of patients with glioblastoma multiforme.
2 Commerce Drive Cranbury, NJ 08512